Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE EVOTEC'S INDUSTRY-LEADING CAPABILITIES IN THE DISCOVERY OF COVALENT INHIBITORS HAMBURG, GERMANY / ACCESSWIRE / February 9, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced today that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences ("RS"), to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec's industry-leading capabilities across the full R&D continuum. Launched in early 2021, the Evotec-RS partnership brings together a unique set of complementary capabilities to efficiently select, discover, and develop new, precisely targeted medicines for unmet patient needs.

Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership

HAMBURG, GERMANY / ACCESSWIRE / February 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take over from Enno Spillner whose contract will expire at the end of March and who will pursue new opportunities.

Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer

STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen.

Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies

Bristol-Myers

THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMBURG, GERMANY / ACCESSWIRE / December 16, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY). The collaboration expands the portfolio by two additional drug discovery projects and has designated a target-based programme for further development, triggering payments in total of US$ 26 m to Evotec.

Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec is a company that partners with biopharma companies to help with their drug discovery programs. With a focus on high growth omics industries, the opportunity for growth is vast.

Evotec SE: Profitable, Innovative, And The Omics Opportunity

Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets Christian Ehmann - Warburg Research James Quigley - Morgan Stanley Derik de Bruin - Bank of America Peter Welford - Jefferies Joe Hedden - Rx Securities Steven Mah - Cowen Falko Friedrichs - Deutsche Bank Victoria English - Evernow Publishing Limited Werner Lanthaler Good morning, good afternoon. Welcome from Evotec.

Evotec SE (EVOTF) Q3 2022 Earnings Call Transcript

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022

AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC'S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX,)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.

Evotec Completes Acquisition of Central Glass Germany

TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR GLOBAL ACCESS TO BIOLOGICS BY APPLYING A FULLY INTEGRATED, END-TO-END CONTINUOUS BIOMANUFACTURING PROCESS JUST - EVOTEC BIOLOGICS SELECTED FOR A SECOND AWARD UNDER THE US DEPARTMENT OF DEFENSE ACCELERATED ANTIBODIES PROGRAM HAMBURG, GERMANY / ACCESSWIRE / November 2, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access. The programme entitled: "Paradigm shift in Biologics" will take place at its J.POD ® Redmond, WA (US) facility.

Evotec Presents Paradigm Shift in Biologics at Capital Markets Day

EXTEND AIMS TO DEVELOP DRUG DISCOVERY PARTNERSHIPS WITH LEADING ACADEMIC INSTITUTIONS FROM ITALY TO ACCELERATE THEIR PROMISING THERAPEUTICS FOR COMMERCIALISATION HAMBURG, GERMANY / ACCESSWIRE / October 28, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO today announced the launch of "Extend", a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and Angelini Ventures, the Corporate Venture Capital arm of the multi-business industrial group Angelini Industries. Extend is a joint venture between Evotec, CDP Venture Capital and Angelini Ventures to develop translational drug discovery partnerships with highly renowned universities and research centres in Italy.

Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN'S SYNDROME ("SJS") AND SYSTEMIC LUPUS ERYTHEMATOSUS ("SLE") HANNOVER MEDICAL SCHOOL ("MHH") WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY HAMBURG, GERMANY / ACCESSWIRE / October 25, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered a partnership with Hannover Medical School ("MHH"), one of the leading German universities, to generate a molecular patient database for Sjögren's syndrome ("SjS") and systemic lupus erythematosus ("SLE"). The strategic partnership between Evotec and MHH aims at achieving a better disease understanding of SjS and SLE by creating a unique longitudinal PanOmics database from the analysis of patient material.

Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases

PANHUNTER EMPOWERS ANY SCIENTIST TO ACCESS AND ANALYSE DEEP BIOLOGICAL AND CLINICAL DATA INCLUDING IN PARTICULAR HUGE PANOMICS DATA SETS PANHUNTER ACCELERATES THE R&D PROCESS AND IMPROVES SUCCESS RATES HAMBURG, GERMANY / ACCESSWIRE / October 18, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec's PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years.

Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World

AMGEN TO JOIN LAB150 TO BUILD CANADA'S NEXT GENERATION OF LIFE SCIENCE COMPANIES HAMBURG, GERMANY and TORONTO, ON / ACCESSWIRE / October 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Toronto Innovation Acceleration Partners ("TIAP") today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of US$ 14 m to expedite LAB150 programmes towards the formation of new companies.

Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen

TORONTO, Canada & HAMBURG, Germany--(BUSINESS WIRE)-- #LifeSciences--Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANT / ACCESSWIRE / September 20, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) today announced that the U.S. Department of Defense ("DOD") has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody ("mAb")-based drug product prototypes targeting plague. Plague, an infectious disease caused by the bacterium Yersinia pestis (" Y.

Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

J.POD ® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 HAMBURG, GERMANY / ACCESSWIRE / September 16, 2-022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today officially launched the construction of its J.POD ® biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. J.POD ® Toulouse, France (EU), the second facility of its kind and the first one on European ground, will employ Just - Evotec Biologics' flexible J.POD ® technology to deliver much-needed clinical and commercial manufacturing capacity for biologics.

Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)

EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKILLED TEAM OF APPROX. 60 CHEMISTS HAMBURG, GERMANY / ACCESSWIRE / August 25, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.

Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany

Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets James Quigley - Morgan Stanley Christian Ehmann - Warburg Research Steven Mah - Cowen Derik de Bruin - Bank of America Falko Friedrichs - Deutsche Bank Joseph Hedden - Rx Securities Operator Good day, ladies and gentlemen. And welcome to the Evotec SE Half Year Report 2022 Conference Call.

Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript

BASE BUSINESS, NEW AND EXTENDED ALLIANCES DRIVE 24% GROWTH JUST - EVOTEC BIOLOGICS IN BUILD-UP PHASE - INVESTMENT ON TRACK ACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPY GUIDANCE FOR FULL-YEAR 2022 REFINED HAMBURG, GERMANY / ACCESSWIRE / August 11, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced its financial results for the first half-year of 2022. HIGHLIGHTS EVOTEC CONTINUES ITS STRONG ORGANIC REVENUE GROWTH IN ALL BUSINESS AREAS Group revenues increased by 24% to € 336.9 m (H1 2021: € 271.3 m) driven by strong demand for its base business; like-for-like revenue growth (excluding fx-effects) 19% Continued strong revenue growth momentum: Total EVT Execute revenues (incl.

Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates

Alpine Immune Sciences

JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM TO DEVELOP AN OPTIMISED COMMERCIAL PROCESS FOR ALPN-303, A DUAL BAFF/APRIL INHIBITOR FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER AUTOIMMUNE AND INFLAMMATORY DISEASES HAMBURG, GERMANY & SEATTLE, WA / ACCESSWIRE / August 10, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of their first-in-human program initiated in 2020 in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase I study and anticipated Phase II studies of ALPN-303.

Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

HAMBURG, Germany & SEATTLE--(BUSINESS WIRE)--Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec's Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for

Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

HAMBURG, GERMANY / ACCESSWIRE / August 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Evotec SE Reports First Half-year 2022 Results on 11 August 2022

HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.

Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance

INGELHEIM, Germany & HAMBURG, Germany & MARCY-L'ÉTOILE, France--(BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

AS "EVOTEC CELL ACCELERATOR", THE HIGH-QUALITY CGMP CELL THERAPY MANUFACTURING SITE ADDS CAPACITY AND CAPABILITY EVOTEC'S EVO CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC-BASED CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING HAMBURG, GERMANY / ACCESSWIRE / July 5, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward.

News for Evotec SE Stock (EVO)